DXCM Share Price Performance
US$66.60
-5.78 (-7.99%)
32.7% undervalued intrinsic discount
US$98.96
Fair Value
Price US$66.60
AnalystConsensusTarget US$98.96
Fair ValueUS$98.96
Share PriceUS$66.60
32.7% undervalued intrinsic discount
DexCom, Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 106 Fair Values set on narratives written by author
DXCM Community Narratives
AN
Fair Value US$98.96 32.7% undervalued intrinsic discount
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
0users have liked this narrative
1users have commented on this narrative
54users have followed this narrative
Insurance Reimbursement And Digital Health Integration Will Unlock Global Potential
Key Takeaways Expanded reimbursement and international coverage unlock new patient segments, fueling sustained revenue growth while diversifying global revenue streams. Advances in product innovation, digital integration, and operational efficiencies drive higher margins, recurring revenues, and increased patient loyalty.
0users have liked this narrative
1users have commented on this narrative
54users have followed this narrative
AN
US$98.96
32.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
14.61% p.a.
Profit Margin
21.43%
Future PE
35.18x
Share price in 2028
US$122.97
Snowflake Analysis
DexCom, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
- 1.46
- 58.77%
- 13.29%
- 95.0%
About DXCM
- Founded
- 1999
- Employees
- 10250
- CEO
- WebsiteView website
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
